Bcr-Abl
特异性亚型抑制剂
Bcr-Abl产品
产品目录 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S1021 |
DasatinibDasatinib是一种新型有效的多靶点抑制剂,作用于Abl,Src和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。 |
![]() ![]() Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta. |
|
S1026 |
Imatinib Mesylate (STI571)Imatinib Mesylate (STI571)是一种口服生物有效的Imatinib甲磺酸盐,是一种多靶点抑制剂,作用于v-Abl,c-Kit和PDGFR,在无细胞和细胞试验中,IC50分别为0.6 μM,0.1 μM 和0.1 μM。 |
![]() ![]() THOC5 phospho-Y225 levels were assessed in the populations shown by flow cytometry following 24 h treatment with 5 μM imatinib, 150 nM dasatinib or 5 μM nilotinib. Results are displayed as mean fluorescence intensity (n= 4) ±s.e.m. |
|
S1490 |
Ponatinib (AP24534)Ponatinib (AP24534)是一种新型有效的多靶点抑制剂,在无细胞试验中作用于Abl,PDGFRα,VEGFR2,FGFR1和Src,IC50分别为0.37 nM,1.1 nM,1.5 nM,2.2 nM和5.4 nM。 |
![]() ![]()
RCH-ACV cells were treated with ponatinib(50 nM), PCI-32765(50 nM), or BMS-599626(500 nM) over a time course, and whole-cell extracts were subjected to immunoblot analysis for total or phospho-AKT.
|
|
S1033 |
Nilotinib (AMN-107)Nilotinib (AMN-107)是一种特异性BCR-ABL抑制剂,在小鼠骨髓祖细胞中IC50低于30 nM。 |
![]() ![]() Effect of nilotinib on Bcr-Abl kinase activity in ABCB1- and ABCG2- overexpressing CD34+CD38- cells. K562 parental cells and CD34+CD38- subpopulation isolated from K562 cells were treated with nilotinib at 0.01, 0.1 and 1.0 umol/L for 12 h. Equal amount of protein was loaded for western blot analysis as described in the Experimental section. The experiments were repeated at least three times independently, and a representative experiment is shown. |
|
S1107 |
Danusertib (PHA-739358)Danusertib (PHA-739358)是一种Aurora kinase抑制剂,作用于Aurora A/B/C,无细胞试验中IC50为13 nM/79 nM/61 nM,适度有效作用于Abl,TrkA,c-RET和FGFR1,对Lck,VEGFR2/3,c-Kit,CDK2等作用效果稍弱。Phase 2。 |
![]() ![]() Mice bearing subcutaneous allografts of conditional patched mutant tumor cells were treated twice weekly with vehicle (saline) or 30 mg/kg PHA-739358. (B)Images of tumors. (C) Tumor weights. Each point represents a single tumor, and grey lines represent mean tumor weights, which were significantly different between vehicle and PHA-739358 treated mice (p < 0.05, based on paired two-tailed t-test).
|
|
S1134 |
AT9283AT9283是一种有效的JAK2/3抑制剂,无细胞试验中IC50为1.2 nM/1.1 nM;对Aurora A/B,Abl(T315I)也有效。Phase 2。 |
![]() ![]() HEL cells were treated with 0.5, 1 or 5 uM of AT9283 or left untreated for 3 hrs. The expression and phosphorylation state of STAT5 (P-STAT5) and Jak2 (P-Jak2) was assessed by Western blot immunodetection.
|
|
S2243 |
Degrasyn (WP1130)Degrasyn (WP1130)是一种选择性deubiquitinase (DUB: USP5,UCH-L1,USP9x,USP14,和 UCH37)抑制剂,对Bcr/Abl也有抑制作用,也是一种JAK2传感器(不影响20S蛋白酶体)和转录激活剂(STAT)。 |
![]() ![]() Protein expression by western blot analysis of cell lysates from MCF-7, TAMR-4 and 164R-7 cells treated for 3 days with vehicle (0.1% DMSO), 1 uM or 1.5 uM WP1130.
|
|
S1369 |
Bafetinib (INNO-406)Bafetinib (INNO-406)是一种有效的,选择性的,双重Bcr-Abl/Lyn双重抑制剂,无细胞试验中IC50为5.8 nM/19 nM,对T315I突变型的磷酸化没有抑制作用,对PDGFR和c-Kit的作用效果较弱。Phase 2。 |
![]() ![]() (A) The effect of bafetinib at 3 μM on the expression levels of ABCB1 in SW620/Ad300 cells for 24, 48 and 72 h. (B) The effect of bafetinib at 3 μM on the expression level of ABCG2 in NCI-H460/MX20 cells for 24, 48 and 72 h. Equal amounts of total cell lysate were used for each sample. The effect of bafetinib at 3 μM on the subcellular localization of ABCB1 in ABCB1-overexpressing (C) SW620/Ad300 cells and (D) HEK/ABCB1 cells for 24, 48 and 72 h. The effect of bafetinib at 3 μM on the subcellular localization of ABCG2 in ABCG2-overexpressing (E) NCI-H460/MX20 cells and (F) HEK/ABCG2-R482 cells. Scale bar, 10 μm. PI (propidium Iodide, red) counterstains the nuclei.
|
|
S2158 |
KW-2449KW-2449是一种多靶点抑制剂,最有效作用于Flt3,IC50为6.6 nM,作用于Flt3, Bcr-Abl和Aurora A适度有效;对PDGFRβ, IGF-1R, EGFR没有抑制效果。Phase 1。 |
![]() ![]() Western blot analysis of p-histone and histone. 0-10μM KW2449 was added.
|
|
S2202 |
NVP-BHG712NVP-BHG712是一种特异性的EphB4抑制剂,ED50为25 nM,区别于对VEGFR和EphB4的抑制,对c-Raf, c-Src和c-Abl也具有抑制活性,IC50分别为0.395 μM, 1.266 μM和1.667 μM。 |
![]() ![]() |
|
S2622 |
PP121PP121是一种作用于PDGFR, Hck, mTOR, VEGFR2, Src和Abl的多靶点抑制剂,IC50分别为2 nM, 8 nM, 10 nM, 12 nM, 14 nM和18 nM,也抑制DNA-PK,IC50为60 nM。 |
![]() ![]() PP121 induces apoptosis in ATC cells. CAL62 cells were treated with PP121 at the indicated concentrations for 48 h, followed by PI staining. The nuclei were stained with Hoechst and analyzed using a fluorescent microscope. The representative images are shown.
|
|
S2634 |
Rebastinib (DCC-2036)Rebastinib (DCC-2036)是一种Bcr-Abl抑制剂,作用于Abl1(WT)和Abl1(T315I),IC50分别为0.8 nM和4 nM,也抑制SRC, LYN, FGR, HCK, KDR, FLT3,和Tie-2,对c-Kit具有低的抑制活性。Phase 1。 |
![]() ![]() BaF3-T674I cells were exposed to the indicated concentrations of DCC-2036, imatinib or sorafenib for 36 h, the phosphorylated PDGFRα and total PDGFRα were analyzed by immunoblotting. Imatinib was used for comparison.
|
|
S7194 |
GZD824 Dimesylate(HQP1351)GZD824 Dimesylate是新型口服有效的Bcr-Abl抑制剂,作用于Bcr-Abl(WT)和Bcr-Abl(T315I),IC50分别为0.34 nM和0.68 nM。 |
![]() ![]() B. Western blot analysis of phosphorylated Akt, S6 and CrkL in T-ALL cell lines treated for 4 h with 2 μM Imatinib or Nilotinib or 0.1 μM GZD824. Twenty-five μg of protein were blotted to each lane. β-Actin documented equal lane loading. Imatinib, Nilotinib and GZD824 were abbreviated in IMA, NIL and GZD. |
|
S2899 |
GNF-2GNF-2是一种高选择性,非ATP竞争性的Bcr-Abl抑制剂,对Flt3-ITD, Tel-PDGFR, TPR-MET和Tel-JAK1转化的肿瘤细胞没有作用活性。 |
![]() ![]() Cell viability of K562/IR cells and their parental cell lines after exposure to different concentrations of GNF-2 for 72 h.
|
|
S5254 |
Dasatinib hydrochlorideDasatinib hydrochloride is the hydrochloride salt form of dasatinib, an inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. |
||
S5205 |
Nilotinib hydrochlorideNilotinib hydrochloride is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. |
||
S7782 |
Dasatinib MonohydrateDasatinib Monohydrate 是一种新型有效的多靶点抑制剂,作用于靶点Abl,Src 和 c-Kit,IC50分别为 <1 nM,0.8 nM 和 79 nM。 |
![]() ![]() Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta. |
|
S8555 |
Asciminib (ABL001)Asciminib(ABL001)是一种有效的、选择性的ABL1变构抑制剂,Kd值为0.5-0.8 nM,与ABL1的十四酰口袋结合。 |
![]() ![]() Co-immunoprecipitation assays of UT7 BCR–ABL T315I (UT7 B/A T315I) cells with or without ponatinib (20 nm) or ABL001 (4 μm) treatment for 24 h. All protein extracts were immunoprecipitated with an anti-DNM2 antibody and immunoblotted with a pan-anti-p-Tyr antibody (4G10).
|
|
S8134 |
RadotinibRadotinib是一种选择性 BCR-ABL1 酪氨酸激酶抑制剂,IC50 为 34 nM,用于治疗慢性髓性白血病。 |
||
S7269 |
PD173955PD173955 是一种强效的Bcr-Abl抑制剂,IC50为1-2 nM,同时也可抑制Src活性,IC50为22 nM。 |
||
S8140 |
GNF-7GNF-7是一种有效的II型激酶Bcr-Abl抑制剂,对M351T,T315I,E255 V,G250E,和 c-Abl的IC50分别为 <5 nM,61 nM,122 nM,136 nM,和 133 nM。 |
||
S7526 |
GNF-5GNF-5 是一种选择性的,变构的Bcr-Abl抑制剂, IC50为220 nM。 |
![]() ![]() IC50 values for GNF-5-treated Ba/F3 cells expressing BCR-ABL1 or ABL1 1b mutants (a) described to confer ABL001 resistance in BCR-ABL1, (b) identified by mutagenesis screen. after 48 hours. Error bars represent SD of triplicates from three independent experiments. Significance levels in comparison with BCR-ABL1 are indicated (NS, not significant; *P<0.05, **P<0.01, ***P<0.001, two-tailed unpaired t-test).
|
|
s9141 |
BerbamineBerbamine (BA), a traditional Chinese medicines extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB. |
||
S3609 |
Berbamine (dihydrochloride)Berbamine (BBM)是一种从中草药黄芦木中分离而来的双苄基异喹啉类天然产物。它是bcr/abl的新型抑制剂,具有有效的抗白血病活性,是NF-κB的抑制剂。 |
产品目录 | 产品描述 | 文献引用 | 实验数据 |
---|---|---|---|
S1021 |
DasatinibDasatinib是一种新型有效的多靶点抑制剂,作用于Abl,Src和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。 |
![]() ![]() Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta. |
|
S1026 |
Imatinib Mesylate (STI571)Imatinib Mesylate (STI571)是一种口服生物有效的Imatinib甲磺酸盐,是一种多靶点抑制剂,作用于v-Abl,c-Kit和PDGFR,在无细胞和细胞试验中,IC50分别为0.6 μM,0.1 μM 和0.1 μM。 |
![]() ![]() THOC5 phospho-Y225 levels were assessed in the populations shown by flow cytometry following 24 h treatment with 5 μM imatinib, 150 nM dasatinib or 5 μM nilotinib. Results are displayed as mean fluorescence intensity (n= 4) ±s.e.m. |
|
S1490 |
Ponatinib (AP24534)Ponatinib (AP24534)是一种新型有效的多靶点抑制剂,在无细胞试验中作用于Abl,PDGFRα,VEGFR2,FGFR1和Src,IC50分别为0.37 nM,1.1 nM,1.5 nM,2.2 nM和5.4 nM。 |
![]() ![]()
RCH-ACV cells were treated with ponatinib(50 nM), PCI-32765(50 nM), or BMS-599626(500 nM) over a time course, and whole-cell extracts were subjected to immunoblot analysis for total or phospho-AKT.
|
|
S1033 |
Nilotinib (AMN-107)Nilotinib (AMN-107)是一种特异性BCR-ABL抑制剂,在小鼠骨髓祖细胞中IC50低于30 nM。 |
![]() ![]() Effect of nilotinib on Bcr-Abl kinase activity in ABCB1- and ABCG2- overexpressing CD34+CD38- cells. K562 parental cells and CD34+CD38- subpopulation isolated from K562 cells were treated with nilotinib at 0.01, 0.1 and 1.0 umol/L for 12 h. Equal amount of protein was loaded for western blot analysis as described in the Experimental section. The experiments were repeated at least three times independently, and a representative experiment is shown. |
|
S1107 |
Danusertib (PHA-739358)Danusertib (PHA-739358)是一种Aurora kinase抑制剂,作用于Aurora A/B/C,无细胞试验中IC50为13 nM/79 nM/61 nM,适度有效作用于Abl,TrkA,c-RET和FGFR1,对Lck,VEGFR2/3,c-Kit,CDK2等作用效果稍弱。Phase 2。 |
![]() ![]() Mice bearing subcutaneous allografts of conditional patched mutant tumor cells were treated twice weekly with vehicle (saline) or 30 mg/kg PHA-739358. (B)Images of tumors. (C) Tumor weights. Each point represents a single tumor, and grey lines represent mean tumor weights, which were significantly different between vehicle and PHA-739358 treated mice (p < 0.05, based on paired two-tailed t-test).
|
|
S1134 |
AT9283AT9283是一种有效的JAK2/3抑制剂,无细胞试验中IC50为1.2 nM/1.1 nM;对Aurora A/B,Abl(T315I)也有效。Phase 2。 |
![]() ![]() HEL cells were treated with 0.5, 1 or 5 uM of AT9283 or left untreated for 3 hrs. The expression and phosphorylation state of STAT5 (P-STAT5) and Jak2 (P-Jak2) was assessed by Western blot immunodetection.
|
|
S2243 |
Degrasyn (WP1130)Degrasyn (WP1130)是一种选择性deubiquitinase (DUB: USP5,UCH-L1,USP9x,USP14,和 UCH37)抑制剂,对Bcr/Abl也有抑制作用,也是一种JAK2传感器(不影响20S蛋白酶体)和转录激活剂(STAT)。 |
![]() ![]() Protein expression by western blot analysis of cell lysates from MCF-7, TAMR-4 and 164R-7 cells treated for 3 days with vehicle (0.1% DMSO), 1 uM or 1.5 uM WP1130.
|
|
S1369 |
Bafetinib (INNO-406)Bafetinib (INNO-406)是一种有效的,选择性的,双重Bcr-Abl/Lyn双重抑制剂,无细胞试验中IC50为5.8 nM/19 nM,对T315I突变型的磷酸化没有抑制作用,对PDGFR和c-Kit的作用效果较弱。Phase 2。 |
![]() ![]() (A) The effect of bafetinib at 3 μM on the expression levels of ABCB1 in SW620/Ad300 cells for 24, 48 and 72 h. (B) The effect of bafetinib at 3 μM on the expression level of ABCG2 in NCI-H460/MX20 cells for 24, 48 and 72 h. Equal amounts of total cell lysate were used for each sample. The effect of bafetinib at 3 μM on the subcellular localization of ABCB1 in ABCB1-overexpressing (C) SW620/Ad300 cells and (D) HEK/ABCB1 cells for 24, 48 and 72 h. The effect of bafetinib at 3 μM on the subcellular localization of ABCG2 in ABCG2-overexpressing (E) NCI-H460/MX20 cells and (F) HEK/ABCG2-R482 cells. Scale bar, 10 μm. PI (propidium Iodide, red) counterstains the nuclei.
|
|
S2158 |
KW-2449KW-2449是一种多靶点抑制剂,最有效作用于Flt3,IC50为6.6 nM,作用于Flt3, Bcr-Abl和Aurora A适度有效;对PDGFRβ, IGF-1R, EGFR没有抑制效果。Phase 1。 |
![]() ![]() Western blot analysis of p-histone and histone. 0-10μM KW2449 was added.
|
|
S2202 |
NVP-BHG712NVP-BHG712是一种特异性的EphB4抑制剂,ED50为25 nM,区别于对VEGFR和EphB4的抑制,对c-Raf, c-Src和c-Abl也具有抑制活性,IC50分别为0.395 μM, 1.266 μM和1.667 μM。 |
![]() ![]() |
|
S2622 |
PP121PP121是一种作用于PDGFR, Hck, mTOR, VEGFR2, Src和Abl的多靶点抑制剂,IC50分别为2 nM, 8 nM, 10 nM, 12 nM, 14 nM和18 nM,也抑制DNA-PK,IC50为60 nM。 |
![]() ![]() PP121 induces apoptosis in ATC cells. CAL62 cells were treated with PP121 at the indicated concentrations for 48 h, followed by PI staining. The nuclei were stained with Hoechst and analyzed using a fluorescent microscope. The representative images are shown.
|
|
S2634 |
Rebastinib (DCC-2036)Rebastinib (DCC-2036)是一种Bcr-Abl抑制剂,作用于Abl1(WT)和Abl1(T315I),IC50分别为0.8 nM和4 nM,也抑制SRC, LYN, FGR, HCK, KDR, FLT3,和Tie-2,对c-Kit具有低的抑制活性。Phase 1。 |
![]() ![]() BaF3-T674I cells were exposed to the indicated concentrations of DCC-2036, imatinib or sorafenib for 36 h, the phosphorylated PDGFRα and total PDGFRα were analyzed by immunoblotting. Imatinib was used for comparison.
|
|
S7194 |
GZD824 Dimesylate(HQP1351)GZD824 Dimesylate是新型口服有效的Bcr-Abl抑制剂,作用于Bcr-Abl(WT)和Bcr-Abl(T315I),IC50分别为0.34 nM和0.68 nM。 |
![]() ![]() B. Western blot analysis of phosphorylated Akt, S6 and CrkL in T-ALL cell lines treated for 4 h with 2 μM Imatinib or Nilotinib or 0.1 μM GZD824. Twenty-five μg of protein were blotted to each lane. β-Actin documented equal lane loading. Imatinib, Nilotinib and GZD824 were abbreviated in IMA, NIL and GZD. |
|
S2899 |
GNF-2GNF-2是一种高选择性,非ATP竞争性的Bcr-Abl抑制剂,对Flt3-ITD, Tel-PDGFR, TPR-MET和Tel-JAK1转化的肿瘤细胞没有作用活性。 |
![]() ![]() Cell viability of K562/IR cells and their parental cell lines after exposure to different concentrations of GNF-2 for 72 h.
|
|
S5254 |
Dasatinib hydrochlorideDasatinib hydrochloride is the hydrochloride salt form of dasatinib, an inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. |
||
S5205 |
Nilotinib hydrochlorideNilotinib hydrochloride is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. |
||
S7782 |
Dasatinib MonohydrateDasatinib Monohydrate 是一种新型有效的多靶点抑制剂,作用于靶点Abl,Src 和 c-Kit,IC50分别为 <1 nM,0.8 nM 和 79 nM。 |
![]() ![]() Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta. |
|
S8555 |
Asciminib (ABL001)Asciminib(ABL001)是一种有效的、选择性的ABL1变构抑制剂,Kd值为0.5-0.8 nM,与ABL1的十四酰口袋结合。 |
![]() ![]() Co-immunoprecipitation assays of UT7 BCR–ABL T315I (UT7 B/A T315I) cells with or without ponatinib (20 nm) or ABL001 (4 μm) treatment for 24 h. All protein extracts were immunoprecipitated with an anti-DNM2 antibody and immunoblotted with a pan-anti-p-Tyr antibody (4G10).
|
|
S8134 |
RadotinibRadotinib是一种选择性 BCR-ABL1 酪氨酸激酶抑制剂,IC50 为 34 nM,用于治疗慢性髓性白血病。 |
||
S7269 |
PD173955PD173955 是一种强效的Bcr-Abl抑制剂,IC50为1-2 nM,同时也可抑制Src活性,IC50为22 nM。 |
||
S8140 |
GNF-7GNF-7是一种有效的II型激酶Bcr-Abl抑制剂,对M351T,T315I,E255 V,G250E,和 c-Abl的IC50分别为 <5 nM,61 nM,122 nM,136 nM,和 133 nM。 |
||
S7526 |
GNF-5GNF-5 是一种选择性的,变构的Bcr-Abl抑制剂, IC50为220 nM。 |
![]() ![]() IC50 values for GNF-5-treated Ba/F3 cells expressing BCR-ABL1 or ABL1 1b mutants (a) described to confer ABL001 resistance in BCR-ABL1, (b) identified by mutagenesis screen. after 48 hours. Error bars represent SD of triplicates from three independent experiments. Significance levels in comparison with BCR-ABL1 are indicated (NS, not significant; *P<0.05, **P<0.01, ***P<0.001, two-tailed unpaired t-test).
|
|
s9141 |
BerbamineBerbamine (BA), a traditional Chinese medicines extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB. |
||
S3609 |
Berbamine (dihydrochloride)Berbamine (BBM)是一种从中草药黄芦木中分离而来的双苄基异喹啉类天然产物。它是bcr/abl的新型抑制剂,具有有效的抗白血病活性,是NF-κB的抑制剂。 |